Voriconazole and caspofungin cidality against non-albicans Candida species

Infectious Diseases in Clinical Practice

Volumn 15, Issue 4, 2007, Pages 250-253

  Isham, Nancy C ^a   Ghannoum, Mahmoud A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; VORICONAZOLE;

ARTICLE; CANDIDA; DRUG INHIBITION; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; NONHUMAN;

EID: 34447509298     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/IPC.0b013e318059b94b     Document Type: Article

References (16)

1. Wenzel RP, Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis. 2005;41:S389-S393.
2. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232-1239.
3. Fluckiger U, Marchetti O, Bille J, et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly. 2006;136:447-463.
4. Nivoix Y, Zamfir A, Lutun P, et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect. 2006;52(1):67-74.
5. Kurtz M, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother. 1994;38:1480-1489.
6. Bopp LH, Baltch AL, Ritz WJ, et al. Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages. J Med Microbiol. 2006;55:865-870.
7. Canton E, Peman J, Viudes A, et al. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis. 2003;45:203-206.
8. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - Second Edition. CLSI document M27-A2 (ISBN 1-56238-469-4). CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898 USA; 2002.
9. Ghannoum M, D'Angelo M. Anidulafungin: a potent antifungal that targets Candida and Aspergillus. Infect Dis Clin Pract. 2005;13:1-14.
10. Espinel-Ingroff A, PfallerM, Messer SA, et al. Multicenter Comparison of the Sensititre YeastOne Colorimetric Antifungal Panel with the NCCLS M27-A2 Reference Method for Testing New Antifungal Agents against Clinical Isolates of Candida spp. J Clin Microbiol. 2004;42:718-721.
11. Shin JH, Kook DH, Hwang TJ, et al. Nosocomial cluster of Candida lipolytica fungemia in pediatric patients. Eur J Clin Microbiol Infect Dis. 2000;19:344-349.
12. Belet N, Ciftci E, Ince E, et al. Caspofungin treatment in two infants with persistent fungaemia due to Candida lipolytica. Scand J Infect Dis. 2006;38:559-562.
13. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997;41:2326-2332.
14. Romero M, Canton E, Peman J, et al. Study of in vitro activity of caspofungin on non-Candida albicans yeast strains determined by two methods: M27-A2 and EUCAST. Rev Esp Quimioter. 2004;17:257-262.
15. Majoros L, Kardos G, Szabo B, et al. Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicidal concentration. Antimicrob Agents Chemother. 2005;49:3486-3488.
16. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113:294-299.